{"entity":{"id":"js108","kind":"drug","name":"JS108","aka":[],"tldr":"JS108 is an experimental TROP-2 antibody-drug conjugate whose first clinical study was terminated.","summary":"NCT04601285 describes a humanised anti-TROP2 monoclonal antibody linked to Tub196, given intravenously every three weeks. The study enrolled 25 actual participants and was terminated after the sponsor adjusted its development plan. This study status does not establish that every future JS108 programme has been abandoned.","status":"historic","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04601285","url":"https://clinicaltrials.gov/study/NCT04601285"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04601285"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Antibody-drug conjugate","mechanism":"Humanised anti-TROP2 antibody conjugated to the microtubule inhibitor Tub196.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/js108/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct04601285","kind":"trial","name":"A Phase I Study of JS108 in Patients With Advanced Solid Tumors","route":"/trials/nct04601285/"}]}}